Editorially independent content, supported with advertising
10.15.21
Cytomegalovirus (CMV) retinitis continues to challenge retina specialists. Could use of CMV-specific cytotoxic T lymphocytes be an effective strategy in some patients? And if so, in whom? To answer these questions, Christina Weng, MD, MBA, is joined by study author Mrinali Gupta, MD, and panelists Brian Do, MD, and Dimitra Skondra, MD, PhD. During their discussion, we hear about the structure and findings of the study and learn about how these new data may affect treatment algorithms for patients with newly diagnosed CMV retinitis. This editorially independent podcast is supported with advertising.
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
06.20.25
Photobiomodulation for Age-related Macular DegenerationModerator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD
03.21.25
Rates of Ocular AEs After Faricimab InjectionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
12.19.24
Switching from Aflibercept to Faricimab in Wet AMD PatientsBen Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,
11.21.24
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?Moderator Rebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
10.17.24
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis PreventionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
09.17.24
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAOKatherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD
08.29.24
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF TherapyBen Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD,
07.19.24
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol ACRebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
Show More